Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

966 related articles for article (PubMed ID: 17705178)

  • 1. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
    Das S; Roth CP; Wasson LM; Vishwanatha JK
    Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal transducer and activator of transcription 6 (STAT6) is a novel interactor of annexin A2 in prostate cancer cells.
    Das S; Shetty P; Valapala M; Dasgupta S; Gryczynski Z; Vishwanatha JK
    Biochemistry; 2010 Mar; 49(10):2216-26. PubMed ID: 20121258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
    Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
    Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
    Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
    Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins.
    Tang DG; Li L; Chopra DP; Porter AT
    Cancer Res; 1998 Aug; 58(15):3466-79. PubMed ID: 9699682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
    Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
    Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
    Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
    Rehman I; Azzouzi AR; Cross SS; Deloulme JC; Catto JW; Wylde N; Larre S; Champigneuille J; Hamdy FC
    Hum Pathol; 2004 Nov; 35(11):1385-91. PubMed ID: 15668896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.
    Wang H; McKnight NC; Zhang T; Lu ML; Balk SP; Yuan X
    Cancer Res; 2007 Jan; 67(2):528-36. PubMed ID: 17234760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
    Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
    Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 14-3-3sigma is down-regulated in human prostate cancer.
    Urano T; Takahashi S; Suzuki T; Fujimura T; Fujita M; Kumagai J; Horie-Inoue K; Sasano H; Kitamura T; Ouchi Y; Inoue S
    Biochem Biophys Res Commun; 2004 Jul; 319(3):795-800. PubMed ID: 15184053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
    Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
    Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of homeobox gene GBX2 expression inhibits human prostate cancer clonogenic ability and tumorigenicity.
    Gao AC; Lou W; Isaacs JT
    Cancer Res; 1998 Apr; 58(7):1391-4. PubMed ID: 9537237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.
    Matsuyama M; Hayama T; Funao K; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R
    Oncol Rep; 2007 Jul; 18(1):99-104. PubMed ID: 17549353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.
    Casimiro M; Rodriguez O; Pootrakul L; Aventian M; Lushina N; Cromelin C; Ferzli G; Johnson K; Fricke S; Diba F; Kallakury B; Ohanyerenwa C; Chen M; Ostrowski M; Hung MC; Rabbani SA; Datar R; Cote R; Pestell R; Albanese C
    Cancer Res; 2007 May; 67(9):4364-72. PubMed ID: 17483350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
    Man YG; Gardner WA
    Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rap2 regulates androgen sensitivity in human prostate cancer cells.
    Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D
    Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appearance of angiotensin II expression in non-basal epithelial cells is an early feature of malignant change in human prostate.
    Louis SN; Wang L; Chow L; Rezmann LA; Imamura K; MacGregor DP; Casely D; Catt KJ; Frauman AG; Louis WJ
    Cancer Detect Prev; 2007; 31(5):391-5. PubMed ID: 18031950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate: evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells.
    Armakolas A; Philippou A; Panteleakou Z; Nezos A; Sourla A; Petraki C; Koutsilieris M
    Prostate; 2010 Aug; 70(11):1233-42. PubMed ID: 20564425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
    Yu S; Wang X; Ng CF; Chen S; Chan FL
    Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.